Indivior Pharmaceuticals, Inc. INDV Foreign currency remeasurement (loss) gain on debt
Foreign currency remeasurement (loss) gain on debt at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's foreign currency remeasurement (loss) gain on debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's foreign currency remeasurement (loss) gain on debt?
- Indivior Pharmaceuticals, Inc. (INDV) reported foreign currency remeasurement (loss) gain on debt of $0 in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's foreign currency remeasurement (loss) gain on debt changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's foreign currency remeasurement (loss) gain on debt decreased by 100.0% year-over-year, from $1M to $0.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's foreign currency remeasurement (loss) gain on debt?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's foreign currency remeasurement (loss) gain on debt has grown at a -37.0% compound annual growth rate (CAGR), from $4M to -$1M.
- What does foreign currency remeasurement (loss) gain on debt mean?
- This metric captures the realized and unrealized gains or losses resulting from fluctuations in exchange rates on transactions denominated in currencies other than the company's functional currency. It reflects the impact of global operational volatility on the bottom line before tax considerations. Investors use this to evaluate the effectiveness of a company's foreign exchange risk management and the sensitivity of its earnings to international market movements.